PROLOR Biotech offering expected to bring $32.5M, to advance PhII long-acting hGH
This article was originally published in Scrip
Executive Summary
PROLOR Biotech, a clinical-stage company based in Israel, has announced the pricing of its previously announced underwritten public offering of 6.5 million shares at $5 per share, or a 12% discount to the closing share price 10 May on the AMEX. The firm expects gross proceeds of $32.5 million before expenses. The underwriters also have a 30-day option for additional shares. PROLOR’s shares are traded on both the NYSE-Amex and TASE.